Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

Overview

Prior to a non-urgent blood transfusion, subjects will be randomized to either stopping feeds or continuing feeds. The intervention group will be the placement of a subject in the NPO group. Subjects in the intervention group will have their feedings stopped for a total of 24 hours around the time of the PRBC transfusion. These infants will be given intravenous nutrition during the period of time that they will not be fed. During the transfusion, both groups of subjects will have serum cytokine levels obtained at 3 time intervals- 1) 4 hours pre-transfusion, 2) 2-4 hours post-transfusion, and 3) 20-24 hours post-transfusion.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Detailed Description

Recently many publications have indicated a potential temporal association between packed red blood cell (PRBC) transfusion and the development of NEC in neonates. Although, to date, there is no conclusive evidence indicating a causal role of PRBC transfusion on the development of NEC. Given the growing body of data that support the association of PRBC transfusions and NEC, a common clinical dilemma arises with regard to feeding infants during a blood transfusion. Additionally, it is thought that increased immunomodulation may be exacerbated by any other pro-inflammatory process or insult; thereby leading to a rapidly increasing cascade of pro-inflammatory cytokines which may ultimately lead to gut inflammation and NEC. Prior to a non-urgent PRBC transfusion, subjects will be randomized to either the NPO group or fed group of patients. The intervention will be the placement of a subject in the NPO group. Subjects will be made NPO for a total of 24 hours around the time of the PRBC transfusion. During the transfusion, both groups of subjects will have serum cytokine levels obtained at 3 time intervals- 1) 4 hours pre-transfusion, 2) 2-4 hours post-transfusion, and 3) 20-24 hours post-transfusion.

Interventions

  • Other: NPO
    • Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
  • Other: Control group: continue feedings
    • Feedings will be continued in this group.

Arms, Groups and Cohorts

  • Other: Intervention: NPO
    • Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion. Pro-inflammatory cytokine response will be monitored at 3 times points.
  • Other: Control: Continue feedings
    • Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team. Pro-inflammatory cytokine response will be monitored at 3 times points.

Clinical Trial Outcome Measures

Primary Measures

  • Pro-inflammatory cytokine response
    • Time Frame: 24 hours
    • Evaluate the pro-inflammatory cytokine response in both fed and NPO infants during a transfusion

Participating in This Clinical Trial

Inclusion Criteria

  • Infants born < 31 weeks gestational age – Between 3 and 7 days old at time of consent Exclusion Criteria:

  • Infants with multiple congenital anomalies – Infant with suspected/confirmed genetic anomalies – Infant with suspected/confirmed congenital immune deficiencies

Gender Eligibility: All

Minimum Age: 3 Days

Maximum Age: 6 Months

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Christiana Care Health Services
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrew Ellefson, MD / Neonatal Fellow – Christiana Care Health Services
  • Overall Official(s)
    • Andrew Ellefson, MD, Principal Investigator, Christiana Care Health Services
    • David A Paul, MD, Study Director, Christiana Care Health Services

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.